Skip to main content
FTH
NASDAQ Life Sciences

PIKTOR Hits 33% Confirmed Response Rate in Advanced Endometrial Cancer Phase 2

Tom Rudovsky · Reported by BusinessWire
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$22.5
Mkt Cap
$569.859M
52W Low
$7.45
52W High
$42.143
52W Position info
202% above low
Off High info
47% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

FTH has more than doubled off its 52-week low of $7.45.

Summary

Faeth's lead program PIKTOR, an all-oral serabelisib plus sapanisertib combination given with paclitaxel, produced a 33% confirmed objective response rate (12 of 36 evaluable patients) in advanced endometrioid endometrial cancer patients with PAM pathway mutations who had already failed a median of two prior lines of therapy. The PIK3CA-mutant subgroup did better at 44% (7 of 16), and preliminary median progression-free survival came in at 7.4 months with a 62% six-month PFS rate. Management argues that compares favorably to the 3-4 months typical of salvage chemotherapy and the 6-7 months seen with newer TOPO1-based ADCs, though this is a single-arm study that cannot prove comparative benefit. Safety looks manageable for the population: 64% had grade 3 or higher treatment-related events, neutropenia was the most common at 26% grade 3+, hyperglycemia and stomatitis were mostly low grade, and only 5% discontinued for toxicity with no treatment-related deaths. This follows the August FDA Fast Track designation for the same PIKTOR-plus-paclitaxel regimen and lands a week after Q3 results showed a $20.4 million quarterly loss against $174.8 million in cash that management says funds both PIKTOR trials to topline. The company now says it plans to move toward Phase 3 subject to regulatory alignment; the 8:00 a.m. ET webcast today is the first chance for questions on trial design and timing.

At the time of this announcement, FTH was trading at $22.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $569.9M. The 52-week trading range was $7.45 to $42.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

FTH - Latest Insights

FTH
Nov 03, 2026, 8:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.20
Real-time Price: $19.81 info
Change: +$0.610 (+3%) info
Market Cap: $569.859M info
FTH
Nov 03, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.23
Real-time Price: $19.81 info
Change: +$0.580 (+3%) info
Market Cap: $569.859M info
FTH
Aug 17, 2026, 7:31 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $32.44
Real-time Price: $19.81 info
Change: -$12.63 (-39%) info
Market Cap: $569.859M info
FTH
Aug 04, 2026, 7:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $19.81 info
Change: -$10.19 (-34%) info
Market Cap: $569.859M info
FTH
Aug 04, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $19.81 info
Change: -$10.19 (-34%) info
Market Cap: $569.859M info